Navigation Links
Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
Date:6/1/2009

dels.

EntreMed Vice President and Chief Medical Officer, Carolyn F. Sidor, M.D., M.B.A., commented, "Plans are underway to expand this study and evaluate additional patients with a variety of cancers as well as specifically those with colorectal and ovarian cancers. These additional data will guide our selection of the most promising solid tumor indications for further study in Phase 2. The recent initiation of Phase 1 studies in multiple myeloma and leukemia will allow us to extend the possible indications for ENMD-2076 into hematological malignancies where preclinical data have been encouraging. These data and the initiation of additional studies have added significant value to the program and, in line with the Company's strategy to accelerate the clinical development of ENMD-2076, partnering discussions continue."

To view a copy of the poster and slide presentations, visit Scientific Presentations under the Therapeutic Pathways section of the Company's web site at www.entremed.com.

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the Flt-3 and FGFR3, kinases which have been shown to play important roles in the pathology of hematological cancers.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angioge
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Initial Clinical Results for ENMD-2076
2. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
3. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
4. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
5. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
6. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
7. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
8. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
9. EntreMed to Present at The New York Society of Security Analysts Industry Conference
10. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
11. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... CHICAGO, Ill. , June 1, 2015  AbbVie ... 2015 Healthcare Conference on Thursday, June 4, 2015. ... will participate in a question and answer session at ... webcast of the presentation will be accessible through AbbVie,s ... archived edition of the session will be available later ...
(Date:6/1/2015)... BOSTON , June 1, 2015 Symbiotix ... a $2.3 million Phase 2 Small Business Technology Transfer ... (NIH) National Institute of Allergy and Infectious Diseases (NIAID). ... is developing a novel class of molecular therapeutics ... lead clinical candidate, Polysaccharide A (PSA), is the first ...
(Date:6/1/2015)... N.J. , June 1, 2015  Elusys ... and Drug Administration (FDA) has accepted for filing ... Anthim® (obiltoxaximab) for the treatment and prevention of ... submitted on March 20, 2015. Anthim is a ... Stockpile, the U.S. government,s repository of critical medical ...
Breaking Medicine Technology:Symbiotix Biotherapies Announces $2.3 Million Award from NIH's National Institute of Allergy and Infectious Diseases (NIAID) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 3
... NEW YORK, April 18, 2012 Financial executives in ... excise tax and the burden of its related compliance ... bottom lines, according to a survey conducted by KPMG ... of respondents said their companies are already contemplating actions ...
... NEW YORK, April 18, 2012 ... initiates coverage on Pacira Pharmaceuticals ... price target $18.00. ... is a member of the ...
Cached Medicine Technology:KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 2KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 3
(Date:6/1/2015)... The National Association of Professional ... a 2015-2016 inductee into the NAPW VIP Professional Woman ... prestigious distinction for leadership in academics. With more than ... is the nation’s leading networking organization exclusively for professional ... important distinction,” said NAPW President Star Jones. “She is ...
(Date:6/1/2015)... 2015 The National Association of ... as a 2015-2016 inductee into its VIP Woman of ... distinction for leadership in business. NAPW is the nation’s ... than 700,000 members and over 200 operating Local Chapters. ... honor,” said NAPW President Star Jones. “Her perseverance, work ...
(Date:6/1/2015)... (PRWEB) June 02, 2015 The ... Selma Tansey as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in mental health. ... professional women, boasting more than 700,000 members and over ... Selma with this important honor," said NAPW President Star ...
(Date:6/1/2015)... Dr. Robert G. Schwartz , ... & Rehabilitation, P.A., has published a new article ... therapy for knees, and highlights it as a ... arthroscopy or knee joint replacement. , Dr. Schwartz, ... and Regenerative Medicine, writes that both autologus and ...
(Date:6/1/2015)... June 01, 2015 Ticket Down announces that ... NBA Western Conference Finals and now will face the Cleveland ... be held at the Oracle Arena in Oakland and the ... 2014-15 National Basketball Association season, the Golden State Warriors were ... a team that learned from their playoff failures from the ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Marcia Ditmyer, Vice President of Academy for Academic Leadership, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Selma Tansey, Executive Director of Washington Communities Human Services, Into its VIP Professional Woman of the Year Circle 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 3Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 3
... HealthSystem (NorthShore) now offers a new incision-free procedure to reverse ... ... Evanston, IL (Vocus) March 6, 2009 -- ... procedure to reverse weight gain after gastric bypass surgery., , ...
... Tex Mex Veggie Pockets, Falafel Flats and Burrito Bites at ... Dr. Praeger,s Sensible Foods, the leader in sensible, heart-friendly ... of all-natural frozen foods. The new products include California ... Veggie Pockets, Falafel Flats and Burrito Bites . ...
... U.S. Consumer Product Safety Commission (CPSC) is urging ... monoxide (CO) alarm batteries this Sunday as clocks ... http://www.newscom.com/cgi-bin/prnh/20030904/USCSCLOGO )"Safeguard your family by putting new ... this weekend," said CPSC,s Acting Chairman Nancy Nord. ...
... India) Today World Lung Foundation and the American ... released an online version of the document at TobaccoAtlas.org. ... graphically display how tobacco is devastating both global health ... in Global Economy , According to The Tobacco ...
... Management,s History of Over-Promising & Under-Delivering Bodes Ill ... The LCA-Vision Full Value Committee announced today that ... stockholders of LCA-Vision, Inc.: March 6, 2009Dear Fellow ... with over 11% of the stock, we believe ...
... Screening Legislation Report Card Ranks State Efforts: Finally, More ... first time, more U.S. states have received A grades ... to the 2009 Colorectal Cancer Legislation Report Card. ... health groups and medical professional societies, the report card ...
Cached Medicine News:Health News:NorthShore University HealthSystem Only Hospital in the Region to Use Incisionless Procedure to Reduce Weight Regain 2Health News:NorthShore University HealthSystem Only Hospital in the Region to Use Incisionless Procedure to Reduce Weight Regain 3Health News:Dr. Praeger's Sensible Foods Launches Four New Frozen Food Products 2Health News:Dr. Praeger's Sensible Foods Launches Four New Frozen Food Products 3Health News:Replace Smoke and CO Alarm Batteries This Sunday for Daylight Saving Time 2Health News:New edition of the Tobacco Atlas catalogues catastrophic toll of tobacco worldwide 2Health News:New edition of the Tobacco Atlas catalogues catastrophic toll of tobacco worldwide 3Health News:The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo 2Health News:The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo 3Health News:The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo 4Health News:The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo 5Health News:New Data Reveals That Gaps in Coverage for Those With Private Insurance Are Major Barriers to Colorectal Cancer Screening 2Health News:New Data Reveals That Gaps in Coverage for Those With Private Insurance Are Major Barriers to Colorectal Cancer Screening 3Health News:New Data Reveals That Gaps in Coverage for Those With Private Insurance Are Major Barriers to Colorectal Cancer Screening 4Health News:New Data Reveals That Gaps in Coverage for Those With Private Insurance Are Major Barriers to Colorectal Cancer Screening 5Health News:New Data Reveals That Gaps in Coverage for Those With Private Insurance Are Major Barriers to Colorectal Cancer Screening 6
... SP Surgical Table combines innovation and design ... up to 1,000 lbs. You can safely ... normal and reverse orientation and have virtually ... patients.,The Amsco 3085 SP Table offers the ...
... 1st MPJ IMPLANT SYSTEM is a unique ... of the 1st metatarsal phalangeal joint resulting ... revision of a previous arthroplasty. The ... pain relief, superior function and longevity. ...
... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
... important part in our daily lives. But ... can cause severe handicaps. A decisive consideration ... was to produce a reconstructed joint function ... nearly possible.,The cementless RM Finger System has ...
Medicine Products: